Adverum Biotechnologies (ADVM)
(Delayed Data from NSDQ)
$7.49 USD
-0.01 (-0.13%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $7.48 -0.01 (-0.13%) 7:58 PM ET
2-Buy of 5 2
D Value C Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ADVM 7.49 -0.01(-0.13%)
Will ADVM be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ADVM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ADVM
Wall Street Analysts See a 332.28% Upside in Adverum Biotechnologies (ADVM): Can the Stock Really Move This High?
Ginkgo (DNA) to Report Q2 Earnings: What's in the Cards?
ADVM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is a Beat in the Cards for Incyte (INCY) in Q2 Earnings?
What's in Store for Structure Therapeutics (GPCR) in Q2 Earnings?
Geron (GERN) to Report Q2 Earnings: What's in the Cards?
Other News for ADVM
JMP Securities healthcare analysts hold an analyst/industry conference call
JMP Securities healthcare analysts hold an analyst/industry conference call
Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Adverum Biotechnologies reports inducement grants under Nasdaq listing rule
Adverum Biotechnologies to Participate in Upcoming Fall Investor Conferences